Floatz logo

Talogreptide Mesaroxetan

Biochemical Recurrence of Malignant Neoplasm of Prostate

Clarity Pharmaceuticals Ltdprotein_peptidePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

513 Active assets in the Biochemical Recurrence of Malignant Neoplasm of Prostate cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Talogreptide Mesaroxetan is also rated in:

castration-resistant prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →